openPR Logo
Press release

Asthma Pipeline Outlook 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Therapies, Therapeutic Analysis, MOA, ROA, and Companies by DelveInsight | CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrin

04-30-2024 05:55 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Asthma Clinical Trials

Asthma Clinical Trials

(Albany, USA) Asthma Pipeline Insight offers in-depth analysis of over 90+ companies and more than 100+ pipeline medications within the Asthma treatment landscape.

DelveInsight's 'Asthma Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline asthma therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the asthma pipeline domain.

To know more about the Asthma pipeline report, click here @ https://www.delveinsight.com/report-store/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Asthma Pipeline Report
• DelveInsight's asthma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for asthma treatment.
• Leading asthma companies such as Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others are evaluating new asthma drugs to improve the treatment landscape.
• Emerging asthma pipeline therapies in various stages of development include CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.
• On February 2024, AstraZeneca announced results of a Prospective, Observational, Real-World Evidence Study (ASCENT): Asthma Control in Severe Asthma Patients Treated With Tezepelumab.
• On November 2023, Regeneron Pharmaceuticals announced results of a study whose aim is to characterize the patients who initiate treatment for asthma with DUPIXENT® in a real-world setting to understand the attributes of treated patients in real life.
• On February 2024, AstraZeneca announced results of a Phase 4, Multicenter, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics.
• On November 2023, GlaxoSmithKline announced results of a 52-week, Randomised, Double-blind, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
• In February 2023, UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted an Innovation Passport under the Innovative Licensing and Access Pathway (ILAP) to dexpramipexole, an eosinophil lowering small molecule, that has recently entered Phase III clinical development. Dexpramipexole is beig developed by Areteia Therapeutics to inhibit the maturation and release of eosinophils in bone marrow, based on evidence from cell cultures and human biopsies, thereby lowering peripheral blood eosinophil levels.

Request a sample and discover the recent advances in asthma drug treatment @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Asthma Overview
Asthma is a chronic disease of the airways. Asthma is characterized by airway inflammation and spasm. Airways are tubes that transport air into and out of the lungs. Asthmatics cause the inside walls of the airways to become sore and swollen. Because of inflammation and tightening of the muscles surrounding the small airways, the airways in the lungs become narrow. Asthma symptoms include coughing, wheezing, shortness of breath, and chest tightness. Asthma symptoms differ from person to person. A person may have infrequent asthma attacks, have symptoms only when exercising, or have symptoms all of the time. Asthma symptoms are similar to those of many respiratory infections.
A careful clinical history is the first step in asthma diagnosis; identifying the characteristic symptoms and their duration, intensity, and relationship of symptoms with allergen and triggering agent; and the impact of these symptoms on quality of life.

Find out more about drugs for asthma @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Asthma Pipeline Drugs mentioned in the report:
• MM09-MG01: Inmunotek S.L.
• BGF MDI: AstraZeneca
• GSK3511294: GlaxoSmithKline
• FP 025: Foresee Pharmaceuticals
• ADX-629: Aldeyra Therapeutics
• 610: Sunshine Guojian Pharmaceutical
• EDP1867: Evelo Biosciences, Inc.
• CM-326 : Keymed Biosciences
• 9MW1911: Mabwell (Shanghai) Bioscience Co., Ltd.
• Dapansutrile: Olatec Therapeutics
• LNR 125.38: Lanier Biotherapeutics

Learn more about the emerging asthma pipeline therapies @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Asthma Therapeutics Assessment
The asthma pipeline report proffers an integral view of asthma emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Asthma Pipeline Report
• Coverage: Global
• Key Asthma Companies: Mabpharm Limited, Avillion LLP, GlaxoSmithKline, Immunotek SL, AB Science, AstraZeneca, Inmunotek, Sterna Biologics, Verona Pharma, MediciNova, Foresee Pharmaceuticals, T-Balance Therapeutics, Teva Pharmaceutical Industries, Aldeyra Therapeutics, Trio Medicines, AstraZeneca, Cumberland Pharmaceuticals, Concentrx Pharmaceuticals, SolAeroMed, Palobiofarma, Sanofi, Oneness Biotech, Novartis, Keymed Biosciences, Suzhou Connect Biopharmaceuticals, 4D Pharma Plc, Hoffman-La-Roche, Celltrion, Glenmark Pharmaceuticals, Archivel Farma, Siolta Therapeutics, Areteia Therapeutics, TFF Pharmaceuticals, Evelo Biosciences, Sunshine Guojian Pharmaceutical, Mabwell (Shanghai) Bioscience, Kinaset Therapeutics, Akari Therapeutics, KLUS Pharma, Upstream Bio, LEO Pharma, and others.
• Key Asthma Pipeline Therapies: CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, Budesonide/Formoterol, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrine, FP-025, XC8, Tregalizumab, TEV-53275, TEV-48574, ADX-629, TR4, MEDI 3506, Lumicitabine, Ifetroban, Halix(TM) Albuterol, SelK2, S1226, PBF-680, Rilzabrutinib, FB825, FB704A, Dexpramipexole, CSJ117, CM310, CJM112, CBP-201, MRx-4DP0004, RG6314, CT-P39, GBR 310, RUTI, STMC-103H, Voriconazole Inhalation Powder, EDP1867, 610, 9MW1911, KN-002, Nomacopan, A378, Anti mIgE+B-cell, and others.

Dive deep into rich insights for new drugs for asthma treatment; visit @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Asthma Pipeline Report Introduction
2. Asthma Pipeline Report Executive Summary
3. Asthma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Asthma Clinical Trial Therapeutics
6. Asthma Pipeline: Late Stage Products (Pre-registration)
7. Asthma Pipeline: Late Stage Products (Phase III)
7.1.BGF MDI: AstraZeneca
8. Asthma Pipeline: Mid Stage Products (Phase II)
8.1. GSK3511294: GlaxoSmithKline
9. Asthma Pipeline: Early Stage Products (Phase I)
9.1. CM-326: Keymed Biosciences
10. Asthma Pipeline Therapeutics Assessment
11. Inactive Products in the Asthma Pipeline
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Asthma Companies
14. Key Products in the Asthma Pipeline
15. Asthma Unmet Needs
16. Asthma Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

For further information on the asthma pipeline therapeutics, reach out @ https://www.delveinsight.com/sample-request/asthma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Reports:
• 3d Cardiac Mapping System Market: https://www.delveinsight.com/report-store/3d-cardiac-mapping-system-market
• Acute Pulmonary Embolism Market: https://www.delveinsight.com/report-store/acute-pulmonary-embolism-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-neoplasms-market
• Carcinoid Tumor Market: https://www.delveinsight.com/report-store/carcinoid-tumor-market
• Cluster Headache Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Condyloma Market: https://www.delveinsight.com/report-store/condyloma-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Fibrocystic Breast Condition Market: https://www.delveinsight.com/report-store/fibrocystic-breast-condition-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Rhino Conjunctivitis Market: https://www.delveinsight.com/report-store/rhino-conjunctivitis-market
• Ventilator Market: https://www.delveinsight.com/report-store/ventilators-market
• Intracranial Pressure Monitoring Devices Market: https://www.delveinsight.com/report-store/intracranial-pressure-monitoring-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neuroprosthetics Market: https://www.delveinsight.com/blog/neuroprosthetics-market-analysis
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Pharmaceutical Consulting Companies: https://www.delveinsight.com/consulting
• Allergic Conjunctivitis Market: https://www.delveinsight.com/report-store/allergic-conjunctivitis-market
• Biotech Consulting: https://www.delveinsight.com/consulting
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Pruritus Market: https://www.delveinsight.com/report-store/cholestatic-pruritus-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Acute Coronary Syndrome Market: https://www.delveinsight.com/report-store/acute-coronary-syndrome-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market

Contact Us:
Ankit Nigam
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Asthma Pipeline Outlook 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, Therapies, Therapeutic Analysis, MOA, ROA, and Companies by DelveInsight | CMAB007, PT027, GSK3511294, MM09-MG01, Masitinib, BGF MDI, MM09, PT001, SB010, Ensifentrine, Bedoradrin here

News-ID: 3480977 • Views:

More Releases from DelveInsight Business Research

Alcoholic Hepatitis Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Gilead Sciences, Inc., Sanofi, Generon Pharmaceutical Technology (Shanghai) Co., Ltd., Immuron Ltd., and Intercept Pha
Alcoholic Hepatitis Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Alcoholic Hepatitis pipeline constitutes 10+ key companies continuously working towards developing 10+ Alcoholic Hepatitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Alcoholic Hepatitis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alcoholic Hepatitis Market. The Alcoholic
Obesity Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Novel and Emerging Therapies, Clinical Trials, and Treatment Outlook | GlaxoSmithKline, Merck, Alizyme, Bayer, Bristol-Myers Squibb, Currax Pharma, F. Hoffmann-La Roche
Obesity Pipeline Review, 2024 Updates | Latest FDA, EMA, and PMDA Approvals, Nov …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Obesity pipeline constitutes 100+ key companies continuously working towards developing 80+ Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Obesity Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Obesity Market. The Obesity Pipeline report embraces in-depth
AL Amyloidosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millenni
AL Amyloidosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clin …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, AL Amyloidosis pipeline constitutes 10+ key companies continuously working towards developing 10+ AL Amyloidosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "AL Amyloidosis Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market. The
Hematopoietic Stem Cell Transplantation Pipeline and Clinical Trials Assessment 2024: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Orchard Therapeutics, Lisata Therapeutics, Genenta science, Editas Medicine
Hematopoietic Stem Cell Transplantation Pipeline and Clinical Trials Assessment …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Hematopoietic Stem Cell Transplantation pipeline constitutes 20+ key companies continuously working towards developing 20+ Hematopoietic Stem Cell Transplantation treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Hematopoietic Stem Cell Transplantation Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across

All 5 Releases


More Releases for Asthma

Asthma Treatment Market: Increase in Prevalence of Asthma and Rise in Awareness …
Transparency Market Research (TMR) has published a new report on the asthma treatment market for the forecast period of 2019–2027. According to the report, the global asthma treatment market was valued at ~US$ 25 Bn in 2018, and is projected to expand at a CAGR of ~2% from 2019 to 2027. Read Report Overview - https://www.transparencymarketresearch.com/asthma-treatment-market.html Overview Asthma treatment involves two main types of medications: long-term asthma control medications and quick-relief (rescue) medications. Asthma
Anti-Asthma Drugs Market Factors Affecting Market Growth 2018 | Key Type of Asth …
To Track and Analyze Competitive Developments such as Joint Ventures, Strategic Alliances, Mergers and Acquisitions, New Product Developments, and Research and Developments Globally. The all things added in “Global Anti Asthma Drugs Market Research Report – Forecast to 2022” – Avail Prime Report to MRFR Anti-Asthma Drugs Market - Overview With the air pollution rising around the world, the number of asthma patients is also increasing. Therefore the market for the drugs
Asthma-Pipeline Review H2 2017
ReportsWeb.com published “Asthma” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Asthma-Pipeline Review, H2 2017, provides an overview of the Asthma (Respiratory) pipeline landscape. Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow
Landmark Asthma Study Demonstrates Device Choice Determines Asthma Control
Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Plattsburgh, NY, USA -- Monaghan Medical Corporation understands that for those with asthma, particularly children, choosing the device that best delivers their medication is an important consideration. Research has shown that even when using the same metered-dose inhaler (MDI), not all valved holding chambers perform equally well.[1] A landmark
Asthma-Pipeline Review H2 2017
ReportsWeb.com published “Asthma” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Asthma-Pipeline Review, H2 2017, provides an overview of the Asthma (Respiratory) pipeline landscape. Asthma is a chronic disease involving the airways in the lungs. These airways, or bronchial tubes, allow
Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to …
Recent Research, a leading business intelligence provider, has released its latest research report: “Asthma Therapeutics Market to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations.” The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR)